Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Shrinking team NBB
FTE fell two years in a row, from 30.7 to 20.6.
-
Figures corrected NBB
Corrected annual account filed for 2022.
Financials
Financial year 2025
OncoDNA from Charleroi, company number BE0501631837, closed financial year 2025 with a result of € -3.8 million after tax. For that financial year OncoDNA recorded a gross margin of € 2.1 million and equity of € -256,642. Compared with financial year 2024, the result moved from € -5.1 million to € -3.8 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.
€ -256,642
▼ € 1 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3.8 million
▲ 26 % less loss than in 2024
Profit after tax over the fiscal year.
€ 520,609
▼ 51% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -5.6 million.
People and assets in 2025
20.6
▼ 1.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.4 million
▼ 8% vs 2024
€ 114,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 5,576
▼ 30% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3.7 million
▼ 51% vs 2024
€ 287,838 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.
€ 1.3 million
▼ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 345,653
▼ 30% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -439,218 | € 769,457 | € 1,207,167 | € 2,079,905 | ▲ 72% |
| Profit after taxes | € -6,136,714 | € -10,361,774 | € -5,144,460 | € -3,794,003 | ▲ € 1.4 million |
| Equity | € 9,998,313 | € 5,835,113 | € 755,741 | € -256,642 | ▼ € 1 million |
| Total debts | € 9,882,937 | € 7,474,319 | € 10,524,928 | € 5,526,209 | ▼ 47% |
| Cash | € 2,115,883 | € 1,498,428 | € 1,062,076 | € 520,609 | ▼ 51% |
| Retained profit | € -22,330,495 | € -10,361,774 | € -15,506,234 | € -5,616,358 | ▲ € 9.9 million |
| Bank debt | € 7,040,763 | € 4,917,193 | € 7,612,503 | € 3,699,478 | ▼ 51% |
| Balance sheet total | € 19,913,250 | € 13,376,073 | € 11,387,919 | € 5,269,567 | ▼ 54% |
| Employees (FTE) | 31.5 | 30.7 | 22 | 20.6 | ▼ 1.4 |
Key figures of OncoDNA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OncoDNA?
What happened at OncoDNA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3.8 million. Source: NBB ↗
- Geldhof Entreprises SPRL stepped down as director. NBB
- Société Fédérale de Participations et d'Investissement (S.F.P.I.) stepped down as director. NBB
- Charles-André Brouwers stepped down as director. NBB
- François Blondel stepped down as director. NBB
- An Herremans stepped down as director. NBB
- Geldhof Entreprises SPRL became a director. NBB
- Société Fédérale de Participations et d'Investissement (S.F.P.I.) became a director. NBB
In short
From € 6.1 million loss in 2022 to € 3.8 million loss in 2025.
Paid € 22,491 in corporate taxes since 2022.
On average € 101,000 of value added per employee in 2025.
Management
The stake of SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT, AvH Growth Capital, BIO.BE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
OncoDNAThe shares are held by SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT (17.5%), AvH Growth Capital (9.5%) and BIO.BE (4.4%). It owns 100% of Biosequences SLU and 66.1% of Integragen itself.
Directors
According to the 2025 annual accounts
Director · represented by Guy Geldhof
since 2023 · until 2026
Société Fédérale de Participations et d'Investissement (S.F.P.I.)
Director · represented by François Fontaine
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale, COMETSAMBRE, ASCO INDUSTRIES, ZEPHYR - FIN, Sabena Aerospace Engineering, reMYND +58 more
since 2023 · until 2026
Charles-André Brouwers
Director
since 2023 · until 2026
since 2023 · until 2026
An Herremans
Director
Also active at: AANNEMINGSMAATSCHAPPIJ CFE, V.M.A., AGIDENS INTERNATIONAL, BAARBEEK IMMO, Indigo Diabetes, BIO CAP INVEST, TURBO'S HOET GROUP, TURBO'S HOET GROUP FINANCE
since 2023 · until 2026
Shareholders
Participations
Biosequences SLU
100%
Integragen
66.1%
Establishments
Establishment units
Physical locations of this company
Rue Louis Breguet 1
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
PLANETHOSTER-8 - PlanetHoster, CA
DNS
Google Cloud DNS
Domain
Domain
oncodna.com
Registered
2012-08-03
Registrar
Gandi SAS
Expires
2026-08-03
Website info
Features
Security
Details
- Company number
- 0501.631.837
- VAT number
- BE 0501.631.837
- Registered office
- Rue Louis Breguet 1, 6041 Charleroi
- Names & denominations
- OncoDNA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 November 2012
- Peppol
- Active · Active since 20 Nov 2025
- Contact
- oncodna.com [email protected]
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria